These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24661957)

  • 1. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
    Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
    Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 3. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing.
    Andrade P; Gonçalo M
    Contact Dermatitis; 2011 Feb; 64(2):118-20. PubMed ID: 21210830
    [No Abstract]   [Full Text] [Related]  

  • 4. Fixed drug eruption by etoricoxib confirmed by patch test.
    Sousa AS; Cardoso JC; Gouveia MP; Gameiro AR; Teixeira VB; Gonçalo M
    An Bras Dermatol; 2016; 91(5):652-654. PubMed ID: 27828643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
    Cimbollek S; Quiralte J; Avila R
    N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoricoxib-induced acute generalized exanthematous pustulosis.
    Mäkelä L; Lammintausta K
    Acta Derm Venereol; 2008; 88(2):200-1. PubMed ID: 18311467
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoricoxib-induced erythema-multiforme-like eruption.
    Thirion L; Nikkels AF; Piérard GE
    Dermatology; 2008; 216(3):227-8. PubMed ID: 18182814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed drug eruption and generalised erythema following etoricoxib.
    Augustine M; Sharma P; Stephen J; Jayaseelan E
    Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
    [No Abstract]   [Full Text] [Related]  

  • 11. Etoricoxib-induced fixed drug eruption with positive lesional patch tests.
    Calistru AM; Cunha AP; Nogueira A; Azevedo F
    Cutan Ocul Toxicol; 2011 Jun; 30(2):154-6. PubMed ID: 21108578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib.
    Miroux-Catarino A; Silva L; Amaro C; Ferreira ML; Viana I
    Contact Dermatitis; 2019 Nov; 81(5):388-389. PubMed ID: 31215658
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.
    Steffens JP; Santos FA; Pilatti GL
    J Periodontol; 2011 Sep; 82(9):1238-44. PubMed ID: 21235334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
    Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
    J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
    [No Abstract]   [Full Text] [Related]  

  • 15. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
    Bingham CO; Smugar SS; Wang H; Tershakovec AM
    Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal fixed drug eruption due to celecoxib.
    Bellini V; Stingeni L; Lisi P
    Dermatitis; 2009; 20(3):174-6. PubMed ID: 19470306
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test.
    Arakawa Y; Nakai N; Katoh N
    J Dermatol; 2011 Dec; 38(12):1185-8. PubMed ID: 22103805
    [No Abstract]   [Full Text] [Related]  

  • 18. COX-2 inhibitor.
    Gøtzsche PC; Bjarnason NH
    Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
    [No Abstract]   [Full Text] [Related]  

  • 19. Coxibs: can this class of drugs survive?
    Tabrizchi R
    Vasc Health Risk Manag; 2005; 1(1):5-8. PubMed ID: 17319092
    [No Abstract]   [Full Text] [Related]  

  • 20. Etoricoxib-induced fixed drug eruption: Report of seven cases.
    Martínez Antón MD; Galán Gimeno C; Sánchez de Vicente J; Jáuregui Presa I; Gamboa Setién PM
    Contact Dermatitis; 2021 Mar; 84(3):192-195. PubMed ID: 32666601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.